Obesity is a world health problem since excessive accumulation of fat tissue (or adipose tissue) increases the risk of cardiovascular disease, hypertension, diabetes and some types of cancer.
Research Programmes / Core Facilities
Cell and Developmental Biology
Structural and Computational Biology
Chemistry and Molecular Pharmacology
Core Facilities & Services
Scientists at IRB Barcelona are supported by an extensive range of common core facilities that provide state-of-the-art technologies and scientific services. These facilities are a key asset for our research, allowing the Institute to obtain outstanding results. They are designed to incorporate the most novel technologies available and provide them to our researchers in the shortest time possible.
IRB Barcelona's partnerships, with organisations in areas of mutual interest and expertise, aim to take advantage of the wealth of knowledge, resources and technologies so critical to advancing the field of biomedicine
Selected IRB Barcelona publications
Noticias & Eventos
DOR protein deficiency favours the development of obesity
Marta Vilaseca: "The information provided by mass spectrometry facilitates the understanding of diseases"
Researchers demonstrate the presence of stable beta-amyloid dimers in the brains of patients with Alzheimer’s disease
LAT2 and TAT1 transporters collaborate in the renal reabsorption of neutral amino acids
25AprNew insight in iron metabolism and hereditary hematological diseases
25AprCoordination of Septate Junctions Assembly and Completion of Cytokinesis in Proliferative Epithelial Tissues
26AprTowards the development of a rationally designed RNA toolkit for combined cancer therapy
27AprA single protein complex, multiple forms- Towards uncovering the inherent complexity of protein complexes
Marta Vilaseca (Barcelona, 1970) leads the Mass Spectrometry & Proteomics Co
The most widely used biomarkers for the early detection of Alzheimer’s disease (AD) are currently the concentrations of beta-amyloid and phosphorylated Tau in cerebrospinal fluid.
A scientific team has described for the first time the in vivo synergy action of the neutral amino acid transporters LAT2 and TAT1 and their participation in the renal absorption.